Vivos Inc. Announces Expansion of IsoPet® Animal Cancer Division with Four New Veterinary Clinics Across the United States

Vivos adds four clinics to its IsoPet cancer treatment network, but financial impact remains unquantified.

What the company is saying

Vivos Inc. is announcing the expansion of its IsoPet Animal Cancer Division by onboarding four additional veterinary facilities across Kentucky, North Carolina, California, and Florida. The company highlights the rigorous certification and licensing process required for each clinic, emphasizing the use of Yttrium-90 and the need for state radioactive materials approvals. Named veterinarians and hospital leaders are cited to underscore clinical credibility and geographic reach. The narrative stresses growing demand for IsoPet treatments and the company's efforts to build a scalable, revenue-generating network, supported by domestic manufacturing at its Applied Process Engineering Laboratory in Richland, Washington. Vivos frames this expansion as a key step in its strategy to drive recurring product demand and long-term revenue growth, while also referencing ongoing cost reduction efforts to reach break-even. The tone is confident and forward-looking, though no specific financial or operational results are disclosed.

What the data suggests

The announcement confirms that four veterinary facilities—Veterinary Specialist Partners (Kentucky), Grace Veterinary Hospital (North Carolina), Malibu Coast Animal Hospital (California), and Palm Beach Equine Clinic (Florida)—are actively progressing through the IsoPet certification, licensing, and onboarding process. Each facility is named, with leadership and location details provided, and each is at a different stage of regulatory or operational readiness. The process involves state-level radioactive materials licensing, specialized training, and equipment preparation, indicating a multi-step, time-intensive rollout. The company claims increasing demand at existing clinics but provides no quantitative data on treatments, revenue, or utilization. Manufacturing capacity is established at APEL in Washington, with a stated focus on cost reduction and scalability, but no production volumes, cost figures, or break-even timelines are given. The evidence supports real operational expansion, but the financial trajectory and actual market uptake remain unsubstantiated by numbers.

Analysis

The announcement is upbeat, emphasizing the expansion of the IsoPet® Animal Cancer Division and the onboarding of four new veterinary facilities. While the operational progress—clinics advancing through certification and licensing—is real and supported by named locations and individuals, the majority of the benefits (increased treatment capacity, recurring product sales, profitability) are projected rather than realized. No financial results, revenue, or patient treatment numbers are disclosed, and claims of 'increasing demand' and 'advancing toward profitability' are not substantiated with data. The process to establish each clinic is described as comprehensive and capital-intensive, but the timeline for revenue or profit realization is not immediate, placing benefits in the near-term at best. The narrative inflates the signal by repeatedly referencing growth, demand, and strategic advancement without quantifying progress or financial impact.

Risk flags

• ●Execution risk is high due to the complex, state-specific radioactive materials licensing required for each new clinic. Delays or denials in regulatory approval could stall or prevent clinics from becoming operational, directly impacting the pace of expansion.
• ●There is a lack of disclosed financial data—no revenue, treatment numbers, or cost figures are provided—making it impossible to assess whether the expansion is translating into meaningful commercial traction or simply increasing fixed costs.
• ●The company's claims of growing demand and anticipated recurring product sales are not supported by quantitative evidence, raising the risk that actual market adoption may lag expectations or projections.
• ●Capital intensity is implied by the need for specialized equipment, training, and regulatory compliance at each facility, which could strain resources if recurring revenues do not materialize as forecast.

Bottom line

Vivos Inc. is expanding its IsoPet veterinary cancer treatment network by onboarding four new clinics across the United States, each progressing through a detailed certification and licensing process. The operational expansion is real and involves named facilities and leaders, but the company provides no financial results, revenue data, or quantified demand metrics to support its claims of growth and increasing utilization. The regulatory and training requirements for each clinic introduce significant execution risk and delay the timeline for revenue realization. Manufacturing capacity and cost reduction efforts are in place, but without disclosure of production volumes or break-even analysis, the commercial impact remains unclear. Investors should treat this as evidence of operational progress but remain cautious until Vivos demonstrates that these new clinics translate into measurable revenue and recurring product demand. The most important takeaway is that while the network is expanding, the financial benefits are still unproven and will depend on successful, timely certification and actual market uptake.

Announcement summary

(OTCQB:RDGL) Vivos Inc. announced the continued expansion of its IsoPet ® Animal Cancer Division, with four additional veterinary facilities advancing through the certification, licensing, and onboarding process to offer IsoPet ® cancer treatment. The four facilities are Veterinary Specialist Partners in Louisville, Kentucky, led by Dr. Grace Clark and Dr. Scott Rizzo; Grace Veterinary Hospital in Sherrills Ford, North Carolina, led by Dr. Jean Tuttle; Malibu Coast Animal Hospital in Malibu, California, founded by Dr. Dean Graulich; and Palm Beach Equine Clinic in Wellington, Florida, led by Dr. Robert Brusie. Veterinary Specialist Partners is an established specialty veterinary hospital offering advanced diagnostic, internal medicine, and oncology services, and the addition of IsoPet ® would expand treatment options for companion animals with challenging cancer diagnoses. Grace Veterinary Hospital is progressing through IsoPet ® training and onboarding to introduce an additional localized cancer treatment option for pets in North Carolina and surrounding communities. Malibu Coast Animal Hospital is advancing through California’s radioactive materials licensing process and is positioned to become Vivos’ first IsoPet ® certified clinic in the state, expanding access to treatment on the West Coast. Palm Beach Equine Clinic is progressing through IsoPet ® certification preparations, expanding Vivos’ opportunity to serve the equine oncology market, including horses requiring treatment for solid tumors and other localized cancers. Establishing an IsoPet ® certified veterinary facility requires a comprehensive process, including meeting state radioactive materials licensing requirements, specialized radiation safety education, treatment protocol training, equipment preparation, practical application exercises, and coordinated support through initial treatments. Each new clinic represents an investment in Vivos’ long-term clinical network, with the potential to generate recurring product demand as treatment programs become established. Vivos continues to work closely with its veterinary partners to advance each facility through required milestones while maintaining standards for regulatory compliance, clinical readiness, and quality patient care. The company is seeing increasing demand across its existing certified clinic network as more pet owners seek IsoPet ® treatment for their animals, supporting continued utilization at established clinics and reinforcing the opportunity to expand access through new facilities. The addition of these four facilities reflects growing interest in IsoPet ® among veterinary professionals and strengthens Vivos’ presence across multiple U.S. regions and veterinary specialties. As participating clinics complete certification and begin treating patients, Vivos anticipates increased treatment capacity, broader geographic access, and additional opportunities for recurring IsoPet ® product sales. Domestic IsoPet ® manufacturing capabilities are established at the Company’s Applied Process Engineering Laboratory (APEL) in Richland, Washington, which is focused on reducing production costs to help Vivos reach break-even and advance toward profitability. The company’s focus remains on converting its growing clinic pipeline into fully operational treatment centers, increasing utilization across its certified network, and establishing IsoPet ® as a scalable, revenue-generating business within veterinary oncology. The continued expansion of the IsoPet ® Animal Cancer Division supports Vivos’ broader strategy of growing commercial revenue while advancing its Precision Radionuclide Therapy ™ platform.

Disagree with this article?